...
首页> 外文期刊>Saudi Pharmaceutical Journal >Fluconazole nanoparticles prepared by antisolvent precipitation technique: Physicochemical, in vitro, ex vivo and in vivo ocular evaluation
【24h】

Fluconazole nanoparticles prepared by antisolvent precipitation technique: Physicochemical, in vitro, ex vivo and in vivo ocular evaluation

机译:通过抗溶剂沉淀技术制备的氟康唑纳米颗粒:物理化学,体外,离体和体内疗效

获取原文

摘要

The goal of this research was to prepare and characterize nanonized particles of the antifungal drug, fluconazole (FLZ) using antisolvent precipitation nanonization technique to improve its ocular permeation. The impact of various concentrations of different stabilizers, namely Pluronic F-127 (PL F 127), Kollicoat IR (KL), hydroxypropyl methylcellulose E3 (HPMC), xanthan gum (XG), polyvinyl pyrrolidone K30 (PVP), and sodium lauryl sulfate (SLS) upon the resulting nanoparticles was investigated. Additionally, the ex vivo release of the FLZ nanonized particles from ophthalmic gel bases was studied by using goat cornea, and the ocular pharmacokinetics of appropriate ophthalmic gel base containing optimized drug nanoparticle formula compared to the untreated drug were studied in rabbits. FLZ nanoparticles were successfully prepared with different concentrations of stabilizers. However, the effects of these stabilizers on nanoparticle size and zeta potential values varied according to the concentration and type of stabilizer used. Based on differential scanning calorimetry, the drug was in its amorphous state in the tested nanoparticle formulations. The results of ex vivo ocular diffusion of the FLZ nanoparticle gel formulations revealed an improvement compared to that with the FLZ untreated gel. Nanoparticle formula (F3) prepared by using 5% PL F127 showed small particle size (352?±?6.1?nm) with zeta potential value of ?18.3?mV with highest ex vivo release rate from goat cornea (100% after 6?h). Moreover, the AUCsub0-8h/sub from ocular application of FLZ from sodium alginate gel containing nanoparticle formula F3 was 1.4-fold higher than that after its administration in the untreated formula. Based on our findings, the ophthalmic gel formulations containing FLZ nanoparticles enhanced drug corneal permeation and improved the ocular pharmacokinetic parameters.
机译:本研究的目的是使用抗溶解沉淀纳米化技术制备和表征抗真菌药物,氟康唑(FLZ)的纳米颗粒,以改善其眼渗透。各种浓度不同稳定剂的影响,即Pluronic F-127(Plf 127),Kollicoat IR(KL),羟丙基甲基纤维素E3(HPMC),黄原胶(XG),聚乙烯吡咯烷酮K30(PVP)和十二烷基硫酸钠(SLS)研究了所得纳米颗粒上。另外,通过使用山羊角膜研究了来自眼科凝胶碱的FLZ纳米颗粒的离体释放,并在兔中研究了含有优化的药物纳米粒子配方的适当眼科凝胶碱的眼镜药代动力学。用不同浓度的稳定剂成功制备FLZ纳米颗粒。然而,这些稳定剂对纳米颗粒尺寸和Zeta电位值的影响根据所用稳定剂的浓度和类型而变化。基于差示扫描量热法,该药物在测试的纳米颗粒制剂中处于其非晶态。与用FLZ未处理的凝胶相比,氨基纳米颗粒凝胶制剂的离体眼部扩散的结果显示出改善。通过使用5%PL F127制备的纳米粒子式(F3)显示出小的粒度(352〜±6.1μm),具有Zeta潜在值的α18.3?MV,来自山羊角膜的最高exvivo释放率(6℃后100% )。此外,AUC&亚& 0-8h& / sub&从含藻酸钠凝胶的FLZ的眼睛施用纳米颗粒式F3为1.4倍,在未处理式中给药后的施用高1.4倍。基于我们的研究结果,含有FLZ纳米颗粒的眼科凝胶制剂增强了药物角膜渗透并改善了眼科药代动力学参数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号